<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763876</url>
  </required_header>
  <id_info>
    <org_study_id>C.2019.088</org_study_id>
    <nct_id>NCT04763876</nct_id>
  </id_info>
  <brief_title>Intramuscular Ketorolac at Two Single-Dose Regimens</brief_title>
  <official_title>Comparison of Intramuscular Ketorolac at Two Single-Dose Regimens for Treatment of Acute Musculoskeletal Pain in a Military Emergency Department: A Randomized Controlled Non-Inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Beaumont Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>William Beaumont Army Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate a single 15 mg intramuscular (IM) dose of ketorolac&#xD;
      for analgesic non-inferiority versus a single 60 mg IM dose for the treatment of acute MSK&#xD;
      pain in a military emergency department (ED) that services Department of Defense (DoD),&#xD;
      Department of Veteran Affairs (VA), and foreign military beneficiaries&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to evaluate a single 15 mg IM dose of ketorolac for&#xD;
      analgesic non-inferiority versus a single 60 mg IM dose for the treatment of acute MSK pain&#xD;
      in a military ED that services Department of Defense (DoD), Department of Veteran Affairs&#xD;
      (VA), and foreign military beneficiaries. The authors chose to evaluate 15 mg rather than the&#xD;
      previously identified 10 mg dose for ease of administration as ketorolac is manufactured in&#xD;
      15 mg/mL, 30 mg/mL, and 60 mg/2mL vials in the U.S. The dose of ketorolac served as the&#xD;
      primary independent variable for the study and the change in Visual Analog Scale (VAS) score&#xD;
      served as the dependent variable. Prescribing the minimally effective doses of NSAIDs is&#xD;
      pertinent to prevent and reduce the number of adverse events. Thus, the secondary outcome&#xD;
      assessed for the dose-dependence of subjective and objective adverse events with ketorolac.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2020</start_date>
  <completion_date type="Actual">November 9, 2020</completion_date>
  <primary_completion_date type="Actual">November 9, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single blinded, randomized, non-inferiority</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The patient was unaware of the dosage of ketorolac they received.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean difference of Visual Analog Scale scores between the two groups</measure>
    <time_frame>60 minutes from administration of medication</time_frame>
    <description>The mean difference of Visual Analog Scale scores between the two treatment groups measured at 60-minutes. The Visual Analog Scale used measures from 0 mm to 100mm. A higher score represents more degree of change. 13 mm was used as the non-inferiority margin. A difference between the two groups less than 13 mm demonstrates that 15 mg is non-inferior to 60 mg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean difference of Visual Analog Scale scores between the two groups</measure>
    <time_frame>30 minutes from administration of medication</time_frame>
    <description>The mean difference of Visual Analog Scale scores between the two treatment groups measured at 60-minutes. The Visual Analog Scale used measures from 0 mm to 100mm. A higher score represents more degree of change. 13 mm was used as the non-inferiority margin. A difference between the two groups less than 13 mm demonstrates that 15 mg is non-inferior to 60 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events related to the administration of ketorolac</measure>
    <time_frame>At time of administration, 30 minutes after administration, and 60 minutes after administration.</time_frame>
    <description>The incidence of observed objective and reported subjective adverse events related to the administration of ketorolac.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Musculoskeletal Pain</condition>
  <condition>Analgesia</condition>
  <condition>Adverse Event</condition>
  <arm_group>
    <arm_group_label>15 mg ketorolac intramuscular</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who received a single 15 mg dose of ketorolac administered intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 mg ketorolac intramuscular</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who received a single 60 mg dose of ketorolac administered intramuscularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Injection 15 mg</intervention_name>
    <description>A single dose of 15 mg ketorolac administered intramuscularly.</description>
    <arm_group_label>15 mg ketorolac intramuscular</arm_group_label>
    <other_name>toradol</other_name>
    <other_name>ketorolac tromethamine</other_name>
    <other_name>ketorolac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Injection 60 mg</intervention_name>
    <description>A single dose of 60 mg ketorolac administered intramuscularly.</description>
    <arm_group_label>60 mg ketorolac intramuscular</arm_group_label>
    <other_name>Toradol</other_name>
    <other_name>ketorolac tromethamine</other_name>
    <other_name>ketorolac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Tricare beneficiaries between 18-55 years of age&#xD;
&#xD;
          -  Triaged as Emergency Severity Index 4 or 5&#xD;
&#xD;
          -  Presenting to the William Beaumont Army Medical Center Emergency Department with a&#xD;
             chief complaint of acute MSK pain (i.e., general muscular, neck, back, shoulder, arm,&#xD;
             forearm, elbow, wrist, finger, hip, knee, thigh, leg, ankle, foot, or digits)&#xD;
&#xD;
          -  Pain intensity of 20 mm or greater on a standard 100 mm visual analog scale&#xD;
&#xD;
          -  Who the attending provider concurred with ketorolac IM administration for analgesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body weight less than 50 kg (110 lbs.)&#xD;
&#xD;
          -  Younger than 18 or older than 55 years&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  History of: confirmed, unconfirmed, known, unknown, or suspected peptic ulcer disease,&#xD;
             intestinal hemorrhage, renal insufficiency, hepatic insufficiency, cerebrovascular&#xD;
             bleeding, hemorrhagic diathesis, incomplete hemostasis, dark stools, bright red blood&#xD;
             per rectum, hemoptysis, easy bruising, or high risk of bleeding&#xD;
&#xD;
          -  Unable to confidently convey or unknown medical history&#xD;
&#xD;
          -  Allergy or hypersensitivity to nonsteroidal anti-inflammatory drugs or aspirin&#xD;
&#xD;
          -  Systolic blood pressure &lt;90 or &gt;180 mmHg&#xD;
&#xD;
          -  Pulse rate &lt;50 or &gt;150 beats/min&#xD;
&#xD;
          -  Any over-the-counter or prescribed opioid and/or non-opioid analgesic medication&#xD;
             (oral, per rectum, topical or parenteral) taken within 12 hours of ED presentation&#xD;
&#xD;
          -  Advised by any medical provider to not receive NSAIDs for any reason&#xD;
&#xD;
          -  Pain duration greater than 30 days (including acute on chronic pain)&#xD;
&#xD;
          -  Refusal to remain in the WBAMC ED for up to 60 minutes after injection of ketorolac&#xD;
&#xD;
          -  Patients currently taking anticoagulant medications&#xD;
&#xD;
          -  Concurrent use of medications which are contraindicated with concomitant NSAID use&#xD;
             (drugs include aspirin, probenecid and pentoxifylline).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathaniel J Turner, MPAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Emergency Medicine, William Beaumont Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Beaumont Army Medical Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>emergency department</keyword>
  <keyword>ketorolac</keyword>
  <keyword>musculoskeletal pain</keyword>
  <keyword>non-inferiority</keyword>
  <keyword>adverse event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 5, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT04763876/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 5, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT04763876/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 5, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT04763876/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>April 12, 2021</submitted>
    <returned>May 7, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

